Explore KEYTRUDA® patient profiles
- Jason † A patient with RCC with a high risk of recurrence
- Natasha † A patient with RCC with an intermediate-high risk of recurrence
- Mario † A patient with RCC with an intermediate-high risk of recurrence
- Lydia † A patient with RCC in the M1, NED disease risk category
Explore efficacy and safety profile results for KEYTRUDA® for the adjuvant treatment of adults with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
Discover results from the KEYNOTE-564 trialExplore efficacy and safety profile results for KEYTRUDA® for the adjuvant treatment of adults with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
Discover results from the KEYNOTE-564 trialExplore efficacy and safety profile results for KEYTRUDA® for the adjuvant treatment of adults with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
Discover results from the KEYNOTE-564 trialExplore efficacy and safety profile results for KEYTRUDA® for the adjuvant treatment of adults with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
Discover results from the KEYNOTE-564 trial- Beatrice † A patient with metastatic RCC
- Joe † A patient with metastatic RCC
- Yvette † A patient with metastatic RCC
Explore efficacy and safety profile results for KEYTRUDA® in combination with axitinib in the first-line setting for advanced or metastatic RCC.
Discover results from the KEYNOTE-426 trialExplore efficacy and safety profile results for KEYTRUDA® in combination with axitinib in the first-line setting for advanced or metastatic RCC.
Discover results from the KEYNOTE-426 trialExplore efficacy and safety profile results for KEYTRUDA® in combination with axitinib in the first-line setting for advanced or metastatic RCC.
Discover results from the KEYNOTE-426 trial† Fictitious patient profile. May not be representative of all patients.
BMI=body mass index; CT=computed tomography; ECOG= Eastern Cooperative Oncology Group; IMDC=International Metastatic RCC Database Consortium; M0=distant metastases; N0=without nodal involvement; NED=no evidence of disease; OTC=over the counter; pT=primary tumour; RCC=renal cell carcinoma.
References:
1. Merck Canada Inc. KEYTRUDA® Product Monograph. February 6, 2024.
2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Kidney Cancer. Version 1.2024. © National Comprehensive Cancer Network, Inc. 2024. Available at: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf.
3. Ljungberg B et al. EAU Guidelines on Renal Cell Carcinoma. © European Association of Urology 2023. March 2023. Available at: https://uroweb.org/guidelines/renal-cell-carcinoma.
4. Choueiri TK et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. NEJM. 2021;385: 683‒94.
5. Canil C et al. Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021. Can Urol Assoc J. 2021;15(4):84‒97.
CA-RCC-00170